Using a novel macrocyclic inhibitor of cyclin/CDK (CIR7–2512) or the CDK2 inhibitor tagtociclib, we demonstrated in vitro activity in PRAD that was comparable to EZH2 inhibition. This evidence concerns the gene CDK2 and prostate adenocarcinoma.